Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. FDA accelerated review denial is a blow to Spectrum’s poziotinib
  2. EMA issues positive opinion on biomarker for Parkinson’s trials
  3. New drugs and therapeutic options help the immune system fight cancer
  4. May’s top news stories
  5. US biosimilar setbacks highlight difficulty of cost-effective development

Latest Content

January’s top news stories

Janssen Pharmaceutical Companies of Johnson & Johnson unblinded the Phase III TITAN trial investigating Erleada (apalutamide) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).

Elzonris

Elzonris (tagraxofusp-erzs) for the Treatment of BPDCN

Elzonris™ (tagraxofusp-erzs) is an interleukin-3 receptor alpha chain (CD123) directed cytotoxin that is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and paediatric patients.

DMAb trial for Zika prevention gets FDA approval

The Wistar Institute, Penn Medicine and Inovio Pharmaceuticals have announced the receipt of FDA approval for commencement of a first-in-human clinical trial to probe the safety and tolerability of a new synthetic DNA-encoded monoclonal antibody (DMAb) therapy to prevent Zika virus infection.

2018: The year’s biggest Drug Development Technology stories

The US National Institutes of Health (NIH) has provided funding for a clinical trial to examine the effectiveness of male contraceptive skin gel NES/T, and GlaxoSmithKline (GSK) has started its Phase III trial evaluating Benlysta (belimumab) in combination with rituximab to treat adult patients with systemic lupus erythematosus (SLE). Drug Development Technology wraps up the key headlines from 2018.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top